CN106456739A - 用于诱导免疫应答的新方法 - Google Patents

用于诱导免疫应答的新方法 Download PDF

Info

Publication number
CN106456739A
CN106456739A CN201580030331.2A CN201580030331A CN106456739A CN 106456739 A CN106456739 A CN 106456739A CN 201580030331 A CN201580030331 A CN 201580030331A CN 106456739 A CN106456739 A CN 106456739A
Authority
CN
China
Prior art keywords
compositionss
purposes
methods according
month
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580030331.2A
Other languages
English (en)
Chinese (zh)
Inventor
W.R.小巴劳
M-A.德莫伊蒂
M-N.R.唐纳
N.夸克德
S.T.特默曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN106456739A publication Critical patent/CN106456739A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580030331.2A 2014-04-02 2015-04-02 用于诱导免疫应答的新方法 Pending CN106456739A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405921.6 2014-04-02
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
CN106456739A true CN106456739A (zh) 2017-02-22

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580030331.2A Pending CN106456739A (zh) 2014-04-02 2015-04-02 用于诱导免疫应答的新方法
CN201580016665.4A Active CN106456738B (zh) 2014-04-02 2015-04-02 诱导免疫应答的新方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580016665.4A Active CN106456738B (zh) 2014-04-02 2015-04-02 诱导免疫应答的新方法

Country Status (18)

Country Link
US (3) US10688168B2 (https=)
EP (2) EP3125929B8 (https=)
JP (2) JP6645982B2 (https=)
KR (2) KR20160132115A (https=)
CN (2) CN106456739A (https=)
AR (1) AR099960A1 (https=)
AU (1) AU2015239025B2 (https=)
BE (1) BE1022355B1 (https=)
BR (2) BR112016022463A2 (https=)
CA (2) CA2943007C (https=)
EA (1) EA037405B1 (https=)
ES (2) ES2853773T3 (https=)
GB (1) GB201405921D0 (https=)
IL (1) IL247493B (https=)
MX (3) MX2016012982A (https=)
SG (1) SG11201607086QA (https=)
WO (2) WO2015150567A1 (https=)
ZA (1) ZA201605955B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
KR20230013237A (ko) 2020-03-09 2023-01-26 다이나박스 테크놀로지 코퍼레이션 Tlr9 효능제를 포함하는 대상포진 백신
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182370A (zh) * 1995-04-25 1998-05-20 史密斯克莱·比奇曼生物公司 含有皂苷和固醇的疫苗
CN103249431A (zh) * 2010-12-14 2013-08-14 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
EP2426141B1 (en) * 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
HRP20161606T1 (hr) * 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
MX2011000982A (es) * 2008-07-25 2011-03-02 Glaxosmithkline Biolog Sa La proteina de tuberculosis rv2386c, composiciones y usos de la misma.
PT2315773T (pt) * 2008-07-25 2016-11-23 Glaxosmithkline Biologicals Sa Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
HUE037121T2 (hu) * 2008-07-25 2018-08-28 Glaxosmithkline Biologicals Sa Új készítmények és eljárások
SI2528621T1 (sl) * 2010-01-27 2017-01-31 Glaxosmithkline Biologicals S.A., Modificirani tuberkolozni antigeni
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015161853A1 (en) * 2014-04-24 2015-10-29 Statens Serum Institut New m.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1182370A (zh) * 1995-04-25 1998-05-20 史密斯克莱·比奇曼生物公司 含有皂苷和固醇的疫苗
CN103249431A (zh) * 2010-12-14 2013-08-14 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHERYL L.DAY等: "Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE》 *
H.MCSHANE: "Tuberculosis vaccines:beyond bacille Calmette-Guerin", 《PHILOSOPHICAL TRANSACTIONS.ROYAL SOCIETY OF LONDON.B:BIOLOGICAL SCIENCES.》 *
ISABEL LEROUX-ROELS等: "Improved CD4+T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations:A randomized trial", 《VACCINE》 *
JAIME MONTOYA等: "A Randomized Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults", 《JOURNAL OF CLINICAL IMMUNOLOGY》 *
POLHEMUS等: "Evaluation of RTS,S/ASO2A and RTS,S/AS01B in Adults in a High Malaria Transmission Area", 《PLOS ONE》 *

Also Published As

Publication number Publication date
JP6655549B2 (ja) 2020-02-26
EA037405B1 (ru) 2021-03-25
EP3125930A1 (en) 2017-02-08
SG11201607086QA (en) 2016-09-29
EP3125929B8 (en) 2023-12-27
US10624961B2 (en) 2020-04-21
CN106456738B (zh) 2021-06-29
MX2016012982A (es) 2016-12-07
JP2017511327A (ja) 2017-04-20
EP3125929C0 (en) 2023-11-01
AU2015239025B2 (en) 2018-01-25
BE1022355A1 (fr) 2016-02-16
CA2943007C (en) 2024-01-09
KR20230075525A (ko) 2023-05-31
KR102762440B1 (ko) 2025-02-03
MX2022013912A (es) 2022-12-13
AU2015239025A1 (en) 2016-09-22
MX2016012932A (es) 2016-12-07
CA2943007A1 (en) 2015-10-08
AR099960A1 (es) 2016-08-31
CN106456738A (zh) 2017-02-22
US11951161B2 (en) 2024-04-09
ES2961840T3 (es) 2024-03-14
JP2017511324A (ja) 2017-04-20
ZA201605955B (en) 2019-04-24
JP6645982B2 (ja) 2020-02-14
WO2015150568A1 (en) 2015-10-08
US20200306353A1 (en) 2020-10-01
KR20160132115A (ko) 2016-11-16
US20170112914A1 (en) 2017-04-27
EP3125929A1 (en) 2017-02-08
IL247493B (en) 2022-08-01
EP3125930B1 (en) 2020-12-02
GB201405921D0 (en) 2014-05-14
EA201691638A1 (ru) 2017-04-28
EP3125929B1 (en) 2023-11-01
US20170136110A1 (en) 2017-05-18
BR112016022787A2 (pt) 2018-03-27
ES2853773T3 (es) 2021-09-17
CA2943711A1 (en) 2015-10-08
BE1022355B1 (fr) 2016-03-26
WO2015150567A1 (en) 2015-10-08
US10688168B2 (en) 2020-06-23
BR112016022463A2 (pt) 2017-10-10
IL247493A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
US10441648B2 (en) Mycobacterium antigenic composition
JP6655549B2 (ja) 免疫応答を誘導するための新規方法
ES2631556T3 (es) Formulación de liposomas adecuada para tratar o prevenir la tuberculosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication